key: cord-0932620-93hgg2py
authors: Liu, X.; Long, C.; Xiong, Q.; Ma, J.; Chen, C.; Su, Y.; Hong, K.
title: Inflammation Level Severity and Death in Patients With COVID-19: A Rapid Systematic Review and Meta-Analysis
date: 2020-05-26
journal: nan
DOI: 10.1101/2020.05.20.20108399
sha: 065acf86c6b54b9ccfe8b267bd94844907dfc0ef
doc_id: 932620
cord_uid: 93hgg2py

Background: An association among the use of angiotensin-converting-enzyme(ACE) inhibitors and angiotensin-receptor blockers(ARBs) with the clinical outcomes of coronavirus disease 2019 (COVID-19) is unclear. Methods: PubMed, EMBASE, and the preprint databases MedRxiv and BioRxiv were searched for relevant studies that assessed the association among inflammation level, application of ACEI/ARB, infection severity and death in patients with COVID-19. Odd risks(OR) and 95% confidence interval (CI) were combined using random-effects or fixed models depending on heterogeneity. Results: Eleven studies were included with a total of 33,483 patients. Our review showed ACEI/ARB therapy might be associated with the reduced inflammatory factor (interleukin-6) and elevated level of immune cells(CD3, CD8). Meta-analysis showed no significant increase in the risk of COVID-19 infection(OR:0.95, 95%CI:0.89-1.05) in patients receiving ACEI/ARB therapy, and ACEI/ARB therapy was associated with a decreased risk of severe COVID-19 (OR:0.75, 95%CI: 0.59-0.96) and mortality (OR:0.52, 95%CI: 0.35-0.79). Subgroup analyses showed that, among the general population, application of ACEI/ARB therapy was associated with reduced risks of all-cause death(OR:0.31, 95%CI: 0.13-0.75), and the risk of severe COVID-19(OR:0.79, 95%CI: 0.60-1.05) infection and COVID-19 infection(OR:0.85, 95% CI: 0.66-1.08) were not increased. Among patients with hypertension, the use of an ACEI/ARB was associated with a lower severity of COVID-19(OR:0.73, 95%CI: 0.51-1.03) and lower mortality(OR:0.57, 95%CI: 0.37-0.87), without evidence of an increased risk of COVID-19 infection(OR:1.00, 95%CI: 0.90-1.12). Conclusion: On the basis of the available evidence, this is the first meta-analysis showed that, in general population, the use of ACEI/ARB therapy was safe without an increased risk of COVID-19 infection and with a decreasing trend of severe COVID-19 infection and lower mortality. In patients with hypertension, the use of ACEI/ARB therapy should be encouraged, without increased risk of COVID-19 inflection, and better prognosis (a decreasing trends of severe COVID-19 and reduced all-cause death). Overall, ACEI/ARB therapy should be continued in patients who are at risk for, or have COVID-19, either in general population or hypertension patients. Our results need to be interpreted with caution considering the potential for residual confounders, and more well-designed studies that control the clinical confounders are necessary to confirm our findings. Key Words COVID-19; ACEI/ARB; SARS-COV-2; pneumonia; infectious disease; lung, hypertension

Two authors (L X. and Y.L) independently extracted the study information and the basic 11 characteristics of the articles using a standardized form, including the first author, year of 12 publication, country, sample size, sex ratio, age, sample size, RAAS type, length of follow-up, 13 adjustments for confounders and adjusted odds ratio (OR) with 95% confidence intervals 14 (CIs). Two authors independently used modified Jada scores and Newcastle-Ottawa Scale 15 (NOS) 19 scores to evaluate the quality of the RCTs (randomized controlled trials) and 16 observational studies, respectively. A Jada score >5 and an NOS score >7 were considered high 17 quality scores 20 . 18 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20108399 doi: medRxiv preprint Statistical Analyses 1 RevMan5.3 (Review Manager [RevMan], version 5.3, Cochrane Collaboration) software was 2 used for statistical data processing, and the OR and 95% CIs were used to estimate the effect. 3

Heterogeneity among the studies was analyzed using the I 2 test with the following 4 interpretation: low heterogeneity, defined as I 2 <50%; moderate heterogeneity, defined as 5 I 2 =50% to 75%; and high heterogeneity, defined as I 2 >75% 21 . The meta-analysis was 6 performed using the random effects model when the heterogeneity was more than 25%, 7 otherwise, the fixed effects model was applied. If there were ACEI and ARB subgroups in the 8 study, the combined OR and the 95% CIs were pooled using RevMan5.3 software. If the study 9 did not report the OR directly, count data for outcomes were used to generate unadjusted ORs 10 and 95% CIs. We also excluded reports with unadjusted ORs in the sensitivity analysis to 11 assess the robustness of our results. A funnel plot was used to test for the presence of 12 publication bias, and P value < 0.05 was considered statistically significant. 13

The systematic search of the electronic databases identified 343 articles (PubMed=54, 16 EMBASE=112, Medrxiv=132, ArXiv=45). After excluding duplicates and title/abstracts 17 screened, 22 articles underwent a more detailed full-text assessment, after which a total of 11 18 articles with 33,483 patients were included 8, 10-17, 22, 23 (Figure 1) . 19 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 26, 2020. 

There were 4 articles that evaluated the relationship between ACEI/ARB and level of 13 inflammation in patients with COVID-19 8, 13, 17, 22 , but since the data were not reported in the 14 same unit across studies, they were not pooled; therefore, we conducted a systematic review 15 instead ( Table 2) . Meng et al 8 . first assessed the impact of RAAS inhibitors on the level of 16 inflammation in patients with COVID-19, and although they found no significant change in 17 CRP levels from the peripheral blood in patients receiving ACEI/ARB treatment, IL-6 levels 18

were significantly reduced, and the level of immune cells (CD3, CD8) counts were 19 significantly increased. 20 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20108399 doi: medRxiv preprint

In contrast, another study showed that there was no difference in IL-6 levels, while 1 high-sensitivity C-reactive protein(CRP) test were significantly decreased 13 . A study that 2 included 342 COVID-19 patients with hypertension who had taken ACEI/ARB drugs found 3 that IL-6 levels were significantly reduced, while CRP level show no significantly different 17 . 4

More recently, a multi-center study including 1,128 patients with hypertension and COVID-19 5 reported that the number of patients with high CRP values who had received ACEI/ARB 6 therapy showed no significantly different than in the patients who had not received ACEI/ARB 7 therapy 10 . 8

Two 15, 16 studies including a total of 10,629 patients reviewed the risk of COVID-19 infection, 10 including one general population-based study and one study including patients with 11

hypertension. There was no significant increase in the risk of COVID-19 infection in patients 12 receiving ACEI/ARB therapy (OR=0.95, 95% CI: 0.89-1.02; P=0.14, I 2 =0%), with no 13 significant heterogeneity (Figure 2A ). Subgroup analysis based on population showed that the 14 results did not change in the general population (OR=0.96, 95% CI: 0.89-1.05; P=0.45, I 2 =0%) 15 or in the hypertensive population (OR=1.00, 95% CI: 0.90-1.12; P=1.00) ( Figure 3A) . 16

Eight studies assessed the relationship between the use of ACEI/ARB therapy and severe 18 COVID-19 8, 11, 13-17, 22 , with two reports in the general population 11, 15 , and 6 reports in patients 19

with hypertension 8, 13, 14, 16, 17, 22 . Compared with the non-ACEI/ARB group, the risk of severe 20 COVID-19 infection decreased by 35% (OR=0.75, 95% CI: 0.59-0.96; P=0.02) in patients 21 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20108399 doi: medRxiv preprint treated with an ACEI/ARB, with moderate heterogeneity (I 2 =54%) ( Figure 2B ). However, in 1 the sensitivity analysis, the results were not statistically significant when the unadjusted studies 2 were excluded (OR=0.85, 95% CI: 0.66-1.08; P=0.19). 3 Subgroup analysis showed there was no statistical significant association between the risk 4 of severe COVID-19 infection and ACEI/ARB use either in the general population (OR=0.85, 5 95% CI: 0.66-1.08; P=0.19, I 2 =61%) or in hypertensive patients with (OR=0.73, 95% CI: 6 0.51-1.03; P=0.07, I 2 =55%) ( Figure 3B) . 7

Seven studies reported all-cause mortality in 11,509 patients with COVID-19 8, 10, 12, 13, 17, 22, 23 , 9

and ACEI/ARB therapy was associated with a decreased risk of all-cause mortality (OR: 0.52, 10 95% CI: 0.35-0.79; P=0.002) with modest of heterogeneity (I 2 =46%) ( Figure 2C ).There is no 11 evidence of heterogeneity (I 2 =1%) when one 23 study was excluded, with no change of the 12 conclusion (OR: 0.46, 95% CI: 0.33-0.64; P<0.001). In the sensitivity analysis, the results 13

were not statistically significant when the unadjusted studies were excluded (OR=0.34, 95% CI: 14 0.18-0.63; P=0.007, I 2 =0%). 15

Only one 12 study reported all-cause mortality in COVID-19 patients in the general 16 population, and which found that ACEI/ARB therapy significantly decreased the mortality rate 17 of COVID-19 patients (OR: 0.31, 95% CI: 0.13-0.75; P=0.009). In hypertensive patients, the 18 use of an ACEI/ARB was associated with a decreased risk of all-cause mortality (OR: 0.57, 95% 19 CI: 0.37-0.87; P=0.009) (Figure 3C) . 20 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20108399 doi: medRxiv preprint

Publication bias was not detected in this study, as tests of publication bias are unsuitable when 2 the number of included studies for each outcome is less than 10 24 . 3

Discussion 4

This study was the first systemic assessment of ACEI/ARB therapy and the clinical prognosis 5 of patients infected with COVID-19. We did not find an association between ACEI/ARB 6 therapy and the increased risk of COVID-19 infection either in general population or in 7 hypertensive patients. Moreover, we found that ACEI/ARB therapy could reduce the risk of 8 severe COVID-19; in a subgroup analysis, RAAS inhibitors reduced the risk of severe 9 COVID-19 by 15% and 27% in the general population and the hypertensive population, 10 respectively, although this benefit did not achieve statistical significance. Finally, ACEI/ARB 11 therapy reduced the rate of all-cause death in patients with COVID-19 by 48%, and in the 12 subgroup analysis, use of an ACEI/ARB reduced the all-cause mortality by 69% and 43% for 13 the general population and the hypertensive population, respectively. 14 Studies have shown that, similar to SARS-CoV, SARS-CoV-2 directly binds to the host 15 cell ACE2 receptor which is highly expressed in human lung tissue, gastrointestinal tract, 16 vascular endothelial cells, and arterial smooth muscle cells in vivo 1, 25 . Animal tests have 17

shown that the expression of ACE2 receptors is significantly increased during ACEI/ARB 18 therapy 5 , leading some scholars to worry that the use of RAAS system inhibitors may 19

contribute to the spread of COVID-19 in the population 6 . On April 13 th , 2020, the European 20 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. However, we know that SARS-CoV-2 is mainly transmitted through the respiratory tract 14 ACE2 receptors 1, 30 , and to date, there have been no reports published on the expression of 15 ACE2 receptors in lung tissue after ACEI/ARB treatment, which is an important direction for 16 future study. 17

Our study found that RAAS inhibitors reduced the risk of severe COVID-19 infection by 18 47%, which might be related to the previously confirmed anti-inflammatory effects of RAAS 19 inhibitors 4 . ACEIs and AT1R inhibitors are commonly used RAAS system inhibitors that have 20 been widely used in the treatment of hypertension, diabetic nephropathy, and congestive heart 21 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20108399 doi: medRxiv preprint failure 3 . Lot of studies have shown that RAAS system is an important target for the treatment 1 of acute lung injury 31 . For example, a retrospective analysis showed that ACEIs and AT1R 2 inhibitors can also reduce the incidence of radiation pneumonitis 32 . In patients with severe 3 COVID-19, the levels of many pro-inflammatory factors (e.g., IL-6, IL-2, and TNF-α) were 4 significantly elevated, and levels of regulatory T cells decreased significantly 7 . A 5 non-randomized controlled clinical trial showed that the IL-6 inhibitor tocilizumab could 6 significantly reduce oxygen consumption, imaging abnormalities, and clinical prognosis in 7 patients with COVID-19 33 . Moreover, in patients receiving ACEI/ARB therapy, IL-6 and CRP 8 levels were significantly decreased, and the level of CD3 andCD8 increased significantly 8 . 9

Overall, this evidence suggests that ACEI/ARB therapy might reduce lung injury and infection 10 severity by downregulating inflammation levels in patients with COVID-19. 11

Although we found use of ACEI/ARB was associated with the decreased risk of severe 12 COVID-19 in the overall analysis, this benefit did not reach statistical significance in the 13 sensitive analysis (with excluding unadjusted studies).Furthermore, subgroup analysis showed 14 the benefit was also not statistically significant either the general population or in patients with 15 hypertension. The possible reason for this result may be related to the limited sample size and 16 existence of many confounding factors in the baseline characteristics such as cardiovascular 17 disease, and the use of drugs may affect these results. Age has been proven to be a strong risk 18 factor for both infection with COVID-19 and a higher severity of COVID-19 infection 12 . 19

Additionally, population-based studies have estimated that the prevalence of hypertension 20 range 9.5%-31.2% in COVID-19 patients, and many studies have shown that hypertension can 21 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20108399 doi: medRxiv preprint also significantly increase the severity of COVID-19 34 . Therefore, more studies with large 1 sample sizes with adjusted for these potential confounders are needed to clarify the impact of 2 ACEI/ARB use on the severity of COVID-19 in both the general population and in 3 hypertensive patients. Recently, one multi-center study that included 1,128 adult patients with 4 hypertension also showed that ACEI/ARB use reduced the risk of septic shock by 62% without 5 reducing the risk of other serious complications such as acute respiratory distress syndrome 6 and disseminated intravascular coagulation after matching baseline factors, suggesting that 7 ACEI/ARB therapy led to a different type of severity of COVID-19 10 . Therefore, the effect of 8 RAAS inhibitors on the severity of COVID-19 remains controversial and requires further 9 study. 10

In addition, we found that ACEI/ARB therapy reduced the risk of mortality by 47%, and 11 in the subgroup analysis, this mortality benefit remained significant for both in the general 12 population and in hypertensive patients. These results remained consistent in the sensitivity 13 analysis, which verified the robustness of our study. The number of studies included in the 14 subgroup of general population, however, was relatively limited (N=1) 12 , and the case-control 15 study design increases bias (e.g., recall bias). Finally, we observed that 26.3% of the population 16 carriedhypertension 12 , and studies have shown that COVID-19 patients with hypertension 17 receiving ACEI/ARB therapy have lower mortality compared with those non-hypertensive 18 individuals with COVID-19. It is therefore unclear whether the benefit was attributable to the 19 high proportion of patients with hypertension. Moreover, the study only adjusted for age and 20 sex and did not correct for enough of the potential confounding factors, such as drug use and 21 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20108399 doi: medRxiv preprint hypertension. Therefore, the benefits of RAAS inhibition in the general population with a 1 lower prevalence of hypertension still needs to be confirmed in future research. 2

Our research has several limitations. First, all of the included articles were observational and 4 therefore cannot confirm the cause-and-effect relationship between ACEI/ARB therapy and 5 the clinical prognosis of patients with COVID-19; a large-scale RCT is needed to confirm our 6 results. Second, coexisting conditions such as hypertension have been shown a key prognostic 7 determinant (e.g. severity and mortality) in patients with COVID-19. The guidelines 8 recommend that patients with hypertension and COVID-19 continue their ACEI/ARB therapy, 9 and our study reinforced this recommendation and further showed that the use of ACEI/ARB 10 therapy might be associated with better clinical outcomes in the general population with 11 COVID-19 and in hypertensive patients with COVID-19. However, the benefit of RAAS 12 inhibitors in non-hypertensive patients might differ from those with hypertensive patients. Due 13 to data limitations, we cannot analyze the severity and clinical prognosis of ACEI/ARB 14 therapy in patients with COVID-19 without hypertension. Third, studies have shown that 15 ACEIs and ARBs may play different roles in patients with COVID-19, due to limited data, we 16 were unable to perform subgroup analyses of ACEIs and ARBs. Fourth, some characteristic 17 clinical values (e.g., drug variables) were missing. For example, the specific details of RAAS 18 inhibitors were lacking in all studies, which might have impact on our results. Fifth, 19 considering that all of the included studies were retrospective, the introduction of recall bias 20 was inevitable and may affect the reliability of the conclusions. Sixth, although we did not 21 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20108399 doi: medRxiv preprint register the protocol of this meta-analysis in the PROSPERO database, no relevant protocols of 1 this topic were found in this database at the writing of this review. 2

On the basis of the available evidence, we found that the use of ACEI/ARB therapy was not 4 associated with an increased risk of COVID-19 and that there was a decreased trend between 5 ACEI/ARB use and severe COVID-19 infection in both the general population and in patients 6 with hypertension, although this association was not statistically significant. The risk of 7 all-cause death was decreased with ACEI/ARB therapy in both the general population and in 8 patients with hypertension. Overall, RAAS inhibitors should be continued use in patients who 9 are at risk for, are being evaluated for, or have COVID-19. Our results need to be interpreted 10 with caution considering the potential for residual confounders, and more well-designed 11 studies that control clinical confounders are necessary to confirm our foundlings. None 10

Online Tables I -II  12 13 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 26, 2020. . https://doi.org/10.1101/2020.05.20.20108399 doi: medRxiv preprint 

Anti-hypertensive Angiotensin II receptor 4 blockers associated to mitigation of disease severity in elderly COVID-19 patients

System Blockers and the Risk of Covid-19

Renin-Angiotensin-Aldosterone System Inhibitors and Risk 10 of Covid-19

Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for 13

COVID-19) Infection in Wuhan, China

The PRISMA Group. Preferred reporting 15 items for systematic reviews and meta-analyses: the PRISMA Statement

Mcpheeters ML

Fluoroquinolones increase the 19 risk of serious arrhythmias: A systematic review and meta-analysis

Infectious Diseases 2020. 20 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted May 26, 2020. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 26, 2020.